Repotrectinib has 4 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyp3a Inducers, Mao Inhibitors, Oral Contraceptives. Patients taking Repotrectinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 4
- Major
- 4
Major (4)
- Repotrectinib + Cyp3a Inducers— Concomitant use may decrease repotrectinib plasma concentrations and reduce efficacy of AUGTYRO. Avoid concomitant use.
- Repotrectinib + Mao Inhibitors— Concomitant use may increase repotrectinib exposure and increase incidence and severity of adverse reactions. Avoid conc…
- Repotrectinib + Oral Contraceptives— Repotrectinib decreases progestin or estrogen exposure, reducing contraceptive effectiveness. Avoid concomitant use; use…
- Repotrectinib + P-Gp Or Bcrp Substrates— Concomitant use may increase repotrectinib exposure and increase incidence and severity of adverse reactions. Avoid conc…